Last updated on August 2019

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B


Brief description of study

This trial is conducted globally. The aim of the trial is to investigate the safety and efficacy of nonacog beta pegol (N9-GP) in previously untreated patients with Haemophilia B.

Clinical Study Identifier: NCT02141074

Find a site near you

Start Over

Novo Nordisk Investigational Site

Los Angeles, CA United States
  Connect »

Novo Nordisk Investigational Site

New Orleans, LA United States
  Connect »

Novo Nordisk Investigational Site

Philadelphia, PA United States
  Connect »

Novo Nordisk Investigational Site

Salt Lake City, UT United States
  Connect »

Novo Nordisk Investigational Site

Shizuoka-shi, Shizuoka, Japan
  Connect »